ALECENSA 150 mg tablet uses,@ BlueberryPharma


ALECENSA

ALECENSA 150mg is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).


DESCRIPTION

Alecensa 150mg belongs to second generation oral drug which selectively prohibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is part used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Prohibitions of ALK prevents phosphorylation and following downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.

MECHANISM OF ACTION

Alectinib belongs tyrosine kinase inhibitor whichaims ALK and RET. In nonclinical studies, Alectinibprohibits ALK phosphorylation and ALK-mediated activation of the downstream signalling proteins STAT3 and AKT, and reduced tumor cell viability in multiple cell lines harbouring ALK fusions, amplifications, or activating mutations.

Dosage and Administration

Non- Small Cell Lung Cancer :
The recommended dose is 600mg PO BID until disease progression or unacceptable Renal impairment patients dose is 450mg orally twice daily Alecensa is administrated with food.

PRECAUTIONS

Due to Alecensa administration, Symptomatic bradycardia may have observed; control heart rate and blood pressure regularly 
Alecensa may causes Severe myalgia and elevated CPK resulted; advise patients to report any unexplained muscle pain, tenderness, or weakness; 
Embryo-fetal toxicity: Based on data from animal studies and its mechanism of action, Alecensa can cause fetal harm when administered to pregnant women. 
Renal impairment occurred during Alecensa treatment; incidence of Grade ≥3 renal impairment was 1.7%, of which 0.5% were fatal events.

PREGNANCY

Based on studies of animal and mechanism of action, Alecensa 150mg will cause fetal harm when given to pregnant women Advice the female not to become pregnant while on treatment with Alecensa.

MISSED DOSE 

If the patient vomits after taking a dose of ALECENSA or missed to take a dose, then should not to take an extra dose, but to take the next dose at the regular time, skip the missed dose.

For More Information

Call us :  +91-97890 77748
Mail to : info@blueberrypharma.com

Comments

Post a Comment

Popular posts from this blog

velasof, velasof tablets ,uses - Myapplepharma

VELASOF TABLETS DESCRIPTION : Velasof   is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects. DOSAGE BEFORE THE TREATMENT :  Care should be taken while using HCV medication in patients with HCV/HIV-1co infections, in this case HBV reactivation occurs.  Velasof   tablets are recommended for chronic condition of hepatitis C viral infection related to genotype 1, 2, 3, 4, 5 or 6. The dosing of  Velasof ; The usual recommended dose of  Velasof  is, one tablet should be administered orally as a single dose.  Velasof  tablet consist of 100mg of Velpatasvir & 400mg of Sofosbuvir.. WORKS AS :  This dynamic active moiety is get inserted into HCV RNA with the help of...
Read more

Today peoples are worried about NSLC – Xovoltib 30mg | Myapplepharma

  Xovoltib 30mg Description : Xovoltib 30mg is a prescription drugs which is used under the guidance of medical practioners. Xovoltib 30mg belongs to quinazoline and butanamide derivative which acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER. Indication : Xovoltib 30mg is indicated for treatment a certain type of lung cancer (non-small cell lung cancer) which has spread to other parts of the body. Mechanism : Xovoltib 30mg dose can blocking the activating sites called tyrosine kinases of various proteins within the cell.By stopping these targets, it will target the cancer will shrink.These proteins are most likely to develop cancer growth when the tumor includes the EGFR gene mutation. Precautions : Diarrhae: Most normal condition for people administrating this medications to have diarrhea. Certain situation this diarrhea can be serious. Severe diarrhea can c...
Read more

Sprycel 20mg tablet | Apple pharmaceuticals

Image
Sprycel 20mg Description : Sprycel 20mg belongs to oral dual BCR/ABL and Src group of tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main aim of Sprycel , are BCRABL, SRC, Ephrin’s and GFR. Sprycel 20mg is a prescription drug which used under the supervision of doctor. Indication : Sprycel 20mg   is indicated for the treatment of adult patients having chronic myeloid leukaemia. Sprycel 20mg is indicated for the treatment of adult patients having acute lymphoblastic leukaemia. DRUG INTERACTION :  Sprycel 20mg combination with CYP3A4 inducers will reduces Dasatinib plasma concentration. Sprycel 20mg combination with antacids will decrease Dasatinib plasma concentration. Sprycel 20mg combination with H2 antagonists/proton pump inhibitors will decrease Dasatinib plasma concentration. PRECAUTION :  Using of Sprycel will results in Tumor lysis syndrome; maintain sufficient hydration and correct ur...
Read more